CG Oncology - Funding, Financials, Valuation & Investors

CG Oncology is registered under the ticker NASDAQ:CGON . Their stock opened with $19.00 in its Jan 25, 2024 IPO. CG Oncology is funded by 21 investors. Foresite Capital and TCG …

CouponFollow Extension

$19.00
OFF

CG Oncology - Funding, Financials, Valuation & Investors

4 weeks from now

CG Oncology is registered under the ticker NASDAQ:CGON . Their stock opened with $19.00 in its Jan 25, 2024 IPO. CG Oncology is funded by 21 investors. Foresite Capital and TCG …

crunchbase.com

$317.57
OFF

CG Oncology Stock Price, Funding, Valuation, Revenue & Financial …

4 weeks from now

Jan 25, 2024 · Funding, Valuation & Revenue. 8 Fundings. CG Oncology has raised $317.57M over 8 rounds.. CG Oncology's latest funding round was a IPO for $380M on January 25, …

cbinsights.com

$294
OFF

CG Oncology - Raised $294M Funding From 17 Investors - Tracxn

4 weeks from now

Oct 31, 2024 · CG Oncology has raised a total funding of $294M over 4 rounds from 17 investors. Investors include Foresite Capital, RA Capital Management and 15 others. ... Post money …

tracxn.com

$180
OFF

CG Oncology Lines Up $180m IPO And A $1bn Valuation

4 weeks from now

Jan 19, 2024 · CG Oncology is the latest biotech to take a look at a share listing in the US, aiming to raise around $180 million in the process, in another sign of a possible recovery in biotech …

pharmaphorum.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

4 weeks from now

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

$105
OFF

CG Raises $105M Crossover Round To Fund Phase 3 Cancer Trial

4 weeks from now

Aug 2, 2023 · CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder …

fiercebiotech.com

$47
OFF

CG Oncology Closes $47 Million Series D Financing

4 weeks from now

IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced …

cgoncology.com

$105
OFF

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023 · – Co-led by new investors Foresite Capital and TCGX – – Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval – August 2, 2023, 8:00 …

cgoncology.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

4 weeks from now

Jan 18, 2024 · Adds details on company's business, IPO terms in paragraphs 2-6. Jan 18 (Reuters) - Cancer drug developer CG Oncology said on Thursday it was targeting a valuation …

nasdaq.com

$22
OFF

$22 Million Series C Financing - CG Oncology

4 weeks from now

– Investment to Advance Clinical Development of Oncolytic Immunotherapies in Bladder Cancer and other Solid Tumors – SANTA ANA, Calif., March 18, 2019 – Cold Genesys, Inc., a clinical …

cgoncology.com

$120
OFF

CG Oncology Raises $120 Million In Oversubscribed Series E …

4 weeks from now

Nov 15, 2022 · – Co-led by ORI Capital, Longitude Capital and Decheng Capital, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and …

cgoncology.com

FAQs about CG Oncology - Funding, Financials, Valuation & Investors Coupon?

How much is CG oncology worth?

The company's lead drug targets a sizable addressa... CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq. ...

Will CG oncology raise $100 million in a public offering?

IRVINE, Calif.-- (BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. ...

Is CG oncology a good IPO?

Biotech stocks have fallen about 1% so far this year. With a lead asset in advanced Phase-III testing, CG Oncology, which debuts Thursday on the NASDAQ, is one of the year's most highly anticipated IPOs. The company's lead drug targets a sizable addressa... ...

What is CG oncology IR?

More events are coming soon. CG Oncology Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts. ...

Will CG Oncology GO Public?

The firm aims to list on the Nasdaq under the symbol CGON. CG Oncology has filed to go public with an IPO on the NASDAQ. CG Oncology has received fast track designation and breakthrough designation needed to accelerate US FDA submission. ...

Who is CG oncology?

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. We see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. ...